13 resultats
BACKGROUND OF THE INVENTION
A group of novel phosphatidyl inositol (PI) analogs are found to be effective phospholipase C inhibitors which are useful anti-inflammatory and analgesic agents.
Phospholipase C contained in mouse peritoneal macrophages has been linked to the enhanced turnover of
BACKGROUND OF THE INVENTION
A group of novel sulfonyl or carbonyl inositol (PI) derivatives are found to be effective phospholipase C inhibitors which are useful anti-inflammatory and analgesic agents.
Phospholipase C contained in mouse peritoneal macrophages has been linked to the enhanced turnover
FIELD OF THE INVENTION
The present invention relates to a method of preventing or alleviating different conditions in the body by administering thereto a pharmaceutical composition comprising inositol triphosphate.
BACKGROUND OF THE INVENTION
Even as early as the year 1900, different researchers had
CROSS-REFERENCE TO RELATED APPLICATION
This application is a National Stage entry of International Application No, PCT/FR2009/000595, filed May 20, 2009, which claims priority to French Patent Application No. 08/53357 filed May 23, 2008, the disclosure of the prior application is incorporated in its
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to an arginine silicate inositol complex and its use in the prevention and treatment of a variety of disease states and disorders.
2. Description of the Related Art
Until recently, infectious disease had been the
This application is a 371 of PCT/IT00/00158 filed Apr. 19, 2000.
The present invention relates to a composition for the prevention and/or treatment of cardiovascular and neurocerebral disorders, various tissue anoxic forms, energetic muscular deficits, inflammatory type-abnormalities, blood
FIELD OF THE INVENTION
This invention relates to analgesics, specifically to a method of controlling inflammation and pain.
BACKGROUND OF THE INVENTION
All early attempts at controlling pain were eventually superseded. Shortcomings of effectiveness and negative side effects were the reasons. This
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to the field of cell adhesion molecules and specifically to the use of inositol polyanion compositions for modulating selectin binding.
2. Description of Related Art
Cell adhesion molecules (CAMs) play a role in
FIELD OF THE INVENTION
This invention pertains to the synthesis and use as therapeutic agents of a group of substances with a glycerol backbone or aliphatic chain structure linked to phosphonocholine, phosphinocholine, phosphonoinositol, phosphinoinositol, or other phosphorus-containing head groups.
FIELD OF THE INVENTION
The present invention relates generally to phosphatidylinositol 3-kinase (PI3K) enzymes, and more particularly to selective inhibitors of PI3K activity and to methods of using such materials.
BACKGROUND OF THE INVENTION
Cell signaling via 3'-phosphorylated phosphoinositides
BACKGROUND OF THE INVENTION
The activity of cells can be regulated by external signals that stimulate or inhibit intracellular events. The process by which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response is referred to as signal
FIELD OF THE INVENTION
The present invention generally relates to novel modulators of IP3K kinases and therapeutic applications of such modulators. More particularly, the invention pertains to novel IP3K modulators that modulate T lymphocyte differentiation and function, and to methods of using such
BACKGROUND OF THE INVENTION
The present invention is concerned with an improved antiinflammatory composition and method of treating inflammation which employs a non-steroidal antiinflammatory agent such as piroxicam, or a pharmaceutically acceptable salt thereof (particularly the ethanolamine salt